|
Dr. Schwarz is an expert in the discovery and development of cardiovascular therapeutics, and will oversee the clinical development activities of Cardioxyl. He has 26 years of experience in the pharmaceutical/ biotechnology industry and in government service. His career focus is the development of new cardiovascular therapeutics. Prior to Cardioxyl, Dr. Schwarz oversaw the clinical development activities at Artesian Therapeutics. Since 1998, Dr. Schwarz has been the founder and President of a strategic consulting firm, CV Ventures, LLC. Prior to that, Dr. Schwarz held the positions of: Vice President, Clinical Development and Regulatory Affairs at Texas Biotechnology Corporation (developed Argatoban); Senior Director, Clinical Development at Astra USA; Global Director of the Cardiovascular Clinical Development Program at the Sterling Research Group, Sterling Drug, Inc. (developed milrinone); Deputy Chief, Extramural Cardiology Branch, at the NIH. Dr. Schwarz has planned and directed numerous research programs in cardiovascular therapeutics, including studies of inotropic agents and neurohormonal modulators in CHF, and studies of thrombin inhibitors, IIb/IIIa inhibitors, and thrombolytic agents in acute coronary syndromes. He has served as an adjunct faculty member at two medical schools, and his bibliography lists over 50 publications and two books. | 